| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
|
Medicine details |
|
| Medicine name | vedolizumab (Entyvio®) |
| Formulation | 300 mg powder for concentrate for solution for infusion |
| Reference number | 569 |
| Indication | Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor‑alpha (TNFα) antagonist |
| Company | Takeda UK Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/04/2014 |
| NICE guidance | TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |